Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475523 | 1.00 | ALDH1A1 (0.35) | ALDH1A1GAAMAPTHSD17B10EGFR | |
| SCHEMBL24254608 | 0.79 | ADRA2A (0.37) | ALDH1A1GAAMAPTHSD17B10EGFR | |
| SCHEMBL4481502 | 0.79 | ALDH1A1 (0.50) | ALDH1A1GAAMAPTHSD17B10EGFR | |
| SCHEMBL13681643 | 0.77 | ALDH1A1 (0.34) | ALDH1A1GAAMAPTHSD17B10EGFR | |
| SCHEMBL19433404 | 0.75 | ALDH1A1 (0.35) | ALDH1A1GAAMAPTHSD17B10EGFR | |
| SCHEMBL17491542 | 0.75 | AR (0.40) | ALDH1A1GAAMAPTHSD17B10EGFR | |
| SCHEMBL7275955 | 0.73 | AKR1C4 (0.39) | ALDH1A1MAPTHSD17B10RET | |
| SCHEMBL3681573 | 0.72 | ALDH1A1 (0.37) | ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL31731661 | 0.72 | ALDH1A1 (0.37) | ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL13681607 | 0.70 | AR (0.38) | ALDH1A1GAAMAPTHSD17B10EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287080-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| EP-4352055-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022259204-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287080-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLB | ALDH1A1 2542/4885GAA 1066/4885MAPT 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.